Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus PHENETRON.
PHENERGAN VC vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine